EMA's CHMP Recommends Approvals for 11 Medicines - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

EMA's CHMP Recommends Approvals for 11 Medicines

At its 16-19 September meeting, the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended the approval of two medicines for cancer: Kadcyla for the treatment of metastatic breast cancer and Xofigo for the treatment of castration-resistant prostate cancer.

The committee also gave positive recommendations for three medicines intended to treat neurological disorders: Abilify Maintena for the treatment of schizophrenia; Memantine Accord, a generic medicine, for the treatment of Alzheimer’s disease; and Levodopa Carbidopa Entacapone Sandoz, which was submitted as an informed consent application, for the treatment of adult patients with Parkinson’s disease.

The CHMP recommended that Vitekta should be granted marketing authorization for the treatment of HIV‑1 infection in adults who are infected with HIV‑1 without known mutations associated with resistance to elvitegravir.

Invokana received a positive opinion for marketing authorization for the treatment of type 2 diabetes mellitus.

NovoEight was recommended for marketing authorization for the treatment of haemophilia A; Relvar Ellipta received a positive opinion from the committee for the treatment of asthma and chronic obstructive pulmonary disorder.

The vaccine Fluenz Tetra was recommended for a marketing authorization for the prevention of influenza in children and adolescents 24 months to less than 18 years of age.

The committee recommended that Lidocaine/Prilocaine Plethora should be granted marketing authorization for the treatment of primary premature ejaculation in adult men.

In other decisions, the CHMP recommended an extension to the existing indications for Cimzia, Kineret, Votubia, and Yervoy.

The CHMP started a re-examination procedure for dihydroergotoxine, one of the medicines included in the Article-31 referral procedure on ergot derivatives. The other ergot derivatives in this referral are not included in this re-examination.

The Committee also started a re-examination procedure for metoclopramide-containing medicines.

Source: EMA


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here